A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin
- 9 September 2004
- journal article
- case report
- Published by Springer Nature in Journal of Human Genetics
- Vol. 49 (10) , 582-585
- https://doi.org/10.1007/s10038-004-0188-6
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Current overview of statin-induced myopathyThe American Journal of Medicine, 2004
- GENETIC POLYMORPHISMS OF CYP2C8 IN JAPANESE POPULATIONDrug Metabolism and Disposition, 2003
- Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver MicrosomesDrug Metabolism and Disposition, 2002
- Common allelic variants of cytochrome P4503A4 and their prevalence in different populationsPharmacogenetics, 2002
- Cerivastatin and Reports of Fatal RhabdomyolysisNew England Journal of Medicine, 2002
- Learning from the cerivastatin experienceThe Lancet, 2001
- Clinical Pharmacokinetics of CerivastatinClinical Pharmacokinetics, 2000
- Inhibitory effects of amiodarone and its N‐deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactionsBritish Journal of Clinical Pharmacology, 2000
- In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazoneXenobiotica, 2000
- Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safetyThe American Journal of Cardiology, 1998